查詢結果分析
相關文獻
- Timoptol-XE[feb9] 及Timoptol[feb9] 用於青光眼或高眼壓症病人之比較性研究
- Carteolol (Arteoptic[feb9])之臨床評估及心血管作用--內因性擬交感神經作用之探討
- 青光眼臨床試驗之臨床應用:高眼壓症治療臨床試驗及正常眼壓性青光眼臨床試驗
- 除了降眼壓之外,還有沒有其他方法?談青光眼病人的飲食
- Ocular Complications after a Sub-Tenon Injection of Triamcinolone Acetonide for Uveitis葡萄膜炎病患接受結膜間質下注射Triamcinolone後相關的眼部併發症
- Corneal Opacity and Congenital Glaucoma Associated with Massive Heparan Sulfaturia: Report of One Case
- 碳酸酐酶抑制劑6-Hydroxyethoxy-2-benzothiazole Sulfonamide靜脈注射後之兔眼藥物動力學
- 碳酸酐酶抑制劑6-Hydroxyethoxyzolamide局部點眼後之兔眼藥物動力學
- 抑制細胞增生藥物在青光眼濾過造口術的應用
- 雅鉻雷射虹膜穿孔術於急性隅角閉鎖性青光眼的臨床結果
頁籤選單縮合
題 名 | Timoptol-XE[feb9] 及Timoptol[feb9] 用於青光眼或高眼壓症病人之比較性研究=Comparative Study of Timoptol-Xe[feb9] Versus Timoptol[feb9] in Patients with Open-Angle Glaucoma or Ocular Hypertension |
---|---|
作 者 | 胡兆宇; 翁林仲; 江靜弘; | 書刊名 | 中華民國眼科醫學會雜誌 |
卷 期 | 37:3 1998.09[民87.09] |
頁 次 | 頁241-246 |
分類號 | 418.2323 |
關鍵詞 | 青光眼; 高眼壓症; 降眼壓藥; Timolol; Gelrite; Glaucoma; Ocular hypertension; |
語 文 | 中文(Chinese) |
中文摘要 | 目的:本臨床試驗目的在比較新投予劑型藥物0.5% Timoptol-XE□每日一次與傳 統0.5% Timoptol □每日二次之間的降眼壓效果,以及對於病人心率、血壓的影響。 方法:將四十名青光眼或高眼壓症病人的隨機分為兩組,接受為期十二週的隨機、開放、 兩階段交叉(cross-over)試驗,各階段皆為六週。A組二十人先使用Timoptol-XE□六週後再 使用Timoptol□六週,B組二十人則先使用Timoptol□六週後再使用Timoptol-XE□六週。 在使用此二種藥物之前以及各階段結束時均需測量病人的眼壓、血壓、心率,並詢問病人使 用藥物的不良反應以及偏好使用何種眼藥。 結果:此二種藥物對於降眼壓的效果,以及對血壓、心率的改變,均沒有達到統計上有 意義的差異,對於病人主觀的不良反應以及偏好性也沒有顯著的不同。 結論:雖然Timoptol-XE□每日一次與Timoptol□每日兩次的效果與反應均無差異,但 就減少投予總劑量以及病人用藥的方便性與順從性,Timoptol-XE□仍是種值得一用的降眼 壓藥。 |
英文摘要 | Topical beta-blockers are widely used anti-glau-coma drugs, and usually they are considered the first line drug for various types of glaucoma. Decrease the frequency of instillation without damping the drug effect is a good idea for most of the glaucoma patients who almost need to take these medicines for life. So we decided to perform this clinical trial to evaluate the responses of the topical beta-blocker that was used once a day. Of course, the responses we had concened included favored (reduction of intraocular pressure) and disfavored (bradycardia, hypotension). A 12-week, randomized, open-labeled, two-period cross-over (6 weeks each period) study was designed; 40 subjects with ocular hypertension, primary open-angle glaucoma, or chronic angle- closure glaucoma were included and treated topically with either timolol maleate 0.5% in Gelrite (Timoptol-XE□) once a day or aqueous timolol maleate 0.5% (Timoptol□) twice a day in a random order of drug use for each 6-week period. There was no statistically significant difference in intraocular pressure, blood pressure, and heart rate between these different groups of treatment; neither is in the different sequence and phased. There was also no difference in adverse effects and preference between these two formulations. |
本系統中英文摘要資訊取自各篇刊載內容。